ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
momentum factor · long-only model fund

Foundry Healthcare 52-Week High Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FHIHHYPOTHETICAL MODEL
Since ’99
−97%
Expense Ratio
0.45%
placeholder
Holdings
98
cap-weighted
Inception
Apr 2021
placeholder
Full Sharpe
-0.25
Ann. Return (LS)
-7.5%
Ann. Volatility
29.3%
Max Drawdown
-97.8%
Test Sharpe ’19–26
-0.22
Test FF5 α (ann.)
-5.7%
vs Fama-French 5
Test FF5 α t-stat
-0.68
not significant
Monthly turnover
45%
of the long leg, per rebalance
Cumulative return (LS)
-97%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.53
what this fund holds
Long leg ann. return
7.9%
buyable, long-only
Long-short Sharpe
-0.25
requires shorting
Bottom bucket ann. return
15.4%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

98 of 98 · 100.0% of book
TickerCompanySectorMarket capWeight
1UNH
UNITEDHEALTH GROUP INCHealthcare$386.95B
34.55%
2CVS
CVS HEALTH CORPHealthcare$137.12B
12.24%
3HUM
HUMANA INCHealthcare$48.02B
4.29%
4RPRX
ROYALTY PHARMA PLCHealthcare$33.50B
2.99%
5CNC
CENTENE CORPHealthcare$32.81B
2.93%
6DXCM
DEXCOM INCHealthcare$29.58B
2.64%
7ILMN
ILLUMINA INCHealthcare$28.24B
2.52%
8INCY
INCYTE CORPHealthcare$23.42B
2.09%
9GH
GUARDANT HEALTH INCHealthcare$20.67B
1.85%
10VTRS
VIATRIS INCHealthcare$20.14B
1.80%
11NBIX
NEUROCRINE BIOSCIENCES INCHealthcare$17.18B
1.53%
12JAZZ
JAZZ PHARMACEUTICALS PLCHealthcare$15.53B
1.39%
13DVA
DAVITA INCHealthcare$15.21B
1.36%
14EXEL
EXELIXIS INCHealthcare$14.06B
1.26%
15BTSG
BRIGHTSPRING HEALTH SERVICES INCHealthcare$13.71B
1.22%
16TECH
BIO-TECHNE CORPHealthcare$11.29B
1.01%
17HSIC
HENRY SCHEIN INCHealthcare$10.00B
0.89%
18NUVL
NUVALENT INCHealthcare$9.79B
0.87%
19CORT
CORCEPT THERAPEUTICS INCHealthcare$9.72B
0.87%
20KYMR
KYMERA THERAPEUTICS INCHealthcare$9.52B
0.85%
21GKOS
GLAUKOS CORPHealthcare$9.21B
0.82%
22PTGX
PROTAGONIST THERAPEUTICS INCHealthcare$9.06B
0.81%
23CRNX
CRINETICS PHARMACEUTICALS INCHealthcare$8.84B
0.79%
24OSCR
OSCAR HEALTH INCHealthcare$8.77B
0.78%
25SYRE
SPYRE THERAPEUTICS INCHealthcare$8.70B
0.78%
26IMVT
IMMUNOVANT INCHealthcare$8.27B
0.74%
27PACS
PACS GROUP INCHealthcare$7.30B
0.65%
28MIRM
MIRUM PHARMACEUTICALS INCHealthcare$7.25B
0.65%
29LQDA
LIQUIDIA CORPHealthcare$7.11B
0.63%
30CHE
CHEMED CORPHealthcare$6.77B
0.60%
31HNGE
HINGE HEALTH INCHealthcare$6.74B
0.60%
32XENE
XENON PHARMACEUTICALS INCHealthcare$6.60B
0.59%
33CGON
CG ONCOLOGY INCHealthcare$6.34B
0.57%
34ERAS
ERASCA INCHealthcare$5.96B
0.53%
35TFX
TELEFLEX INCHealthcare$5.96B
0.53%
36DNTH
DIANTHUS THERAPEUTICS INCHealthcare$5.77B
0.52%
37TXG
10X GENOMICS INCHealthcare$5.55B
0.50%
38KNSA
KINIKSA PHARMACEUTICALS INTERNATIONAL PLCHealthcare$4.92B
0.44%
39VCYT
VERACYTE INCHealthcare$4.72B
0.42%
40LFST
LIFESTANCE HEALTH GROUP INCHealthcare$4.49B
0.40%
41CON
CONCENTRA GROUP HOLDINGS PARENT INCHealthcare$4.04B
0.36%
42ICUI
ICU MEDICAL INCHealthcare$3.94B
0.35%
43DYN
DYNE THERAPEUTICS INCHealthcare$3.92B
0.35%
44CPRX
CATALYST PHARMACEUTICALS INCHealthcare$3.85B
0.34%
45RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
0.34%
46NHC
NATIONAL HEALTHCARE CORPHealthcare$3.56B
0.32%
47PRVA
PRIVIA HEALTH GROUP INCHealthcare$3.39B
0.30%
48ELVN
ENLIVEN THERAPEUTICS INCHealthcare$3.24B
0.29%
49MBX
MBX BIOSCIENCES INCHealthcare$2.99B
0.27%
50ESTA
ESTABLISHMENT LABS HOLDINGS INCHealthcare$2.72B
0.24%
51TRVI
TREVI THERAPEUTICS INCHealthcare$2.71B
0.24%
52PGNY
PROGYNY INCHealthcare$2.50B
0.22%
53VCEL
VERICEL CORPHealthcare$2.38B
0.21%
54PVLA
PALVELLA THERAPEUTICS INCHealthcare$2.26B
0.20%
55IOVA
IOVANCE BIOTHERAPEUTICS INCHealthcare$2.23B
0.20%
56SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.20%
57MD
PEDIATRIX MEDICAL GROUP INCHealthcare$2.15B
0.19%
58GLUE
MONTE ROSA THERAPEUTICS INCHealthcare$2.07B
0.19%
59CDNA
CAREDX INCHealthcare$2.05B
0.18%
60RAPP
RAPPORT THERAPEUTICS INCHealthcare$2.04B
0.18%
61PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.18%
62URGN
UROGEN PHARMA LTDHealthcare$1.96B
0.18%
63DMRA
DAMORA THERAPEUTICS INCHealthcare$1.94B
0.17%
64SNDA
SONIDA SENIOR LIVING INCHealthcare$1.93B
0.17%
65NEO
NEOGENOMICS INCHealthcare$1.90B
0.17%
66MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.17%
67HCSG
HEALTHCARE SERVICES GROUP INCHealthcare$1.74B
0.16%
68MPLT
MAPLIGHT THERAPEUTICS INCHealthcare$1.72B
0.15%
69TDOC
TELADOC HEALTH INCHealthcare$1.70B
0.15%
70FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.15%
71PSNL
PERSONALIS INCHealthcare$1.61B
0.14%
72IART
INTEGRA LIFESCIENCES HOLDINGS CORPHealthcare$1.50B
0.13%
73PNTG
PENNANT GROUP INCHealthcare$1.46B
0.13%
74XNCR
XENCOR INCHealthcare$1.30B
0.12%
75DRTS
ALPHA TAU MEDICAL LTDHealthcare$1.19B
0.11%
76ETON
ETON PHARMACEUTICALS INCHealthcare$1.16B
0.10%
77BVS
BIOVENTUS INCHealthcare$1.01B
0.09%
78FBRX
FORTE BIOSCIENCES INCHealthcare$1.00B
0.09%
79TALK
TALKSPACE INCHealthcare$873M
0.08%
80HSTM
HEALTHSTREAM INCHealthcare$832M
0.07%
81MNPR
MONOPAR THERAPEUTICSHealthcare$744M
0.07%
82NGNE
NEUROGENE INCHealthcare$590M
0.05%
83STTK
SHATTUCK LABS INCHealthcare$577M
0.05%
84NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.05%
85NRC
NRC HEALTHHealthcare$491M
0.04%
86VMD
VIEMED HEALTHCARE INCHealthcare$466M
0.04%
87SI
SHOULDER INNOVATIONS INCHealthcare$448M
0.04%
88DCTH
DELCATH SYSTEMS INCHealthcare$442M
0.04%
89PBYI
PUMA BIOTECHNOLOGY INCHealthcare$434M
0.04%
90TBRG
TRUBRIDGE INCHealthcare$394M
0.04%
91ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.03%
92TTRX
TURN THERAPEUTICS INCHealthcare$272M
0.02%
93QTTB
Q32 BIO INCHealthcare$255M
0.02%
94UTMD
UTAH MEDICAL PRODUCTS INCHealthcare$222M
0.02%
95FOCL
FOCAL INCHealthcare$204M
0.02%
96CPIX
CUMBERLAND PHARMACEUTICALS INCHealthcare$103M
0.01%
97ICCC
IMMUCELL CORPHealthcare$101M
0.01%
98RLYB
RALLYBIO CORPHealthcare$87M
0.01%

Full long-leg book as of July 2026 · cap-weighted · total market cap $1.12T. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

98 classified
Value
Blend
Growth
Large
Mid
Small
8%6
51%16
29%19
1%6
2%11
2%10
<1%8
<1%3
<1%9

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 96% toward Large, 62% toward Growth. +6% unclassified (10 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt96% → Large
SmallLarge
Value ↔ growth tilt62% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 98 names now. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
3
Failed
3
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

  • With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.

    Required
    >= 75.0%
    Actual
    63.2%
    Margin
    -11.8%
  • No more than 25% of total assets may be invested in the securities of any one issuer.

    Required
    <= 25.0%
    Actual
    34.6%
    Margin
    -9.6%
  • Days required to liquidate the largest position at 20% of one day's dollar volume.

    Required
    <= 7.0 days
    Actual
    unbounded
    Margin
Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 98 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
1.0 (95% CI 0.6-1.1)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
9.4%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
0.97x
within
parametric
0.94x
within
cornish fisher
1.06x
within

The estimators agree, which is mild evidence the number isn’t an artefact of one method.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2004
Before publication (pre-2004)
-0.50
Sharpe · -20.8% p.a.
January 1999December 2004 · 72 mo
Since publication
-0.15
Sharpe · -3.8% p.a.
January 2005July 2026 · 259 mo
Change in Sharpe+0.34Sharpe strengthened since publication

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
15%
4 of 26 3-year windows made money
Worst window
-1.20
Sharpe, January 2008 – December 2010
January 1999July 2026
Median Sharpe
-0.26
Dispersion
0.46
Best window
0.83

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.38.9%12.2%
3 yearsp.a.4.5%-6.1%
5 yearsp.a.3.4%-4.0%
10 yearsp.a.7.3%-6.7%
Since inceptionp.a.7.0%-11.5%
Calendar years
YearLong legLong-short
20267 mo16.7%26.6%
202512.7%-8.6%
2024-7.2%-16.5%
2023-5.6%-35.5%
2022-1.5%10.5%
20216.0%-0.8%
202016.6%-32.8%
201917.1%-7.1%
201814.3%30.0%
201719.5%6.4%
2016-1.1%19.0%
20150.4%-4.3%
201422.8%-19.3%
201338.1%-4.4%
201217.8%-22.0%
201112.7%19.7%
20102.2%-15.6%
20099.3%-42.4%
2008-18.0%-25.6%
200717.4%16.4%
20064.9%-7.3%
200514.0%18.7%
20046.3%-16.6%
200321.4%-13.5%
2002-18.6%-3.4%
2001-15.7%-50.3%
200014.5%-54.8%
1999-0.1%-2.5%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FHIH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2021-04-10 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$1.12T

Methodology

The Foundry Healthcare 52-Week High Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 52-Week High signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.